GlassScriptPhysician profile
Edward L Singer
NPI 1679569743
$1,314.29
in general payments reported to CMS, 2019-2025
18 companies · $60.10 in 2025
The $60.10 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $61.42 · 2021: $193 · 2022: $276 · 2023: $105 · 2024: $141 · 2025: $60.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.05 | 2019-2025 | Xifaxan |
| Abbvie INC. | $188.79 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Braintree Laboratories, INC. | $167.91 | 2019-2023 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $152.14 | 2019-2024 | |
| Janssen Biotech, INC. | $133.44 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $128.76 | 2019-2022 | |
| Shionogi INC | $43.87 | 2019 | |
| Celgene Corporation | $36.81 | 2022-2024 | Zeposia |
| Romark Laboratories, Lc | $24.95 | 2019 | |
| Madrigal Pharmaceuticals | $23.90 | 2024 | Resmetirom |
| Echosens North America, INC. | $23.49 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $23.02 | 2020 | |
| Blueprint Medicines Corporation | $22.04 | 2023 | |
| Ironwood Pharmaceuticals, INC | $18.98 | 2021 | |
| Evoke Pharma, INC. | $16.31 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $14.88 | 2020 | |
| Redhill Biopharma INC. | $12.12 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.